Field Notes: First QMSR Cycle, First Cracks
What the first months of QMSR enforcement are already revealing about FDA calibration, inspection behavior, and regulatory drift.
1. Makary out. The QMSR rollout just lost its commissioner.
FDA Commissioner Marty Makary resigned Tuesday after the White House signaled his removal the prior Friday, reportedly over a fruit-flavored e-cigarette approval dispute. Acting commissioner is Kyle Diamantas, deputy commissioner for food, who does not hold a medical degree.
The QMSR rule went effective February 2. CP 7382.850 is still being internalized by the cadre that has to inspect against it. Now the top FDA seat sits with a non-physician food-program lead on an acting basis. None of that helps inspection consistency, guidance cadence, or the open QMSR questions vendors have been waiting on.
What I am watching for the next sixty days: a visible signal from CDRH leadership that QMSR enforcement priorities are unchanged. If it does not come, the field offices will start improvising. They already are.
Source: NYT, Politico, RAPS, May 12, 2026.
2. First QMSR inspection cycle: half produce a 483. None classify OAI.
I pulled the post-QMSR window from FDA primary data (2/2/2026 through 4/28/2026): 250 unique device inspections. 119 classified VAI, 131 NAI. Zero classified OAI. That is a 47.6% 483-yielding rate, with the regulatory-action category sitting empty.
Pre-QMSR FY2026 Q1 ran 45.8% 483-yielding with 16 OAI. Prior-year same window ran 51.7% with another 16 OAI. The 483-yielding share is right where it has been. The OAI count is the anomaly. Inspection volume is also down: 250 versus 377 in the prior-year same window, a 33% drop.
That is not inspectors going easy. That is classification authority holding fire while the field calibrates to a new framework. Findings are landing, citations are being written, the official-action lever has not been pulled in three months. OAI classifications often take months to finalize, so this cohort may yet reclassify.
The citation framework flipped overnight: 90.6% of post-QMSR citations are framed against ISO 13485, from 0% pre-rule. Top clauses: §7.1 (product realization risk management, 12.9%), §8.2.2 (complaint handling, 8.1%), §7.4.1 (supplier evaluation, 7.1%), §8.5.2 (CAPA, 6.5%), §7.5.6 (process validation, 5.2%). Internal audit (§8.2.4) and management review (§5.6.1) both surfaced inside the top 10. Under QSR, §820.22 and §820.20(c) rarely cleared that bar.
A 47.6% 483 rate is not a transition discount. If OAIs catch up to the 483 volume already produced, this cohort gets reclassified as a calibration period, not a soft one.
Source: FDA Inspections Dashboard and Citations data, primary-source pull through 2026-04-28.
3. Medline got a QSR-framed warning letter three months into QMSR.
Five CDRH warning letters have been issued since QMSR effective. Three of them, including a March 25 letter to Medline Industries, still carry the legacy CGMP/QSR/Medical Devices/Adulterated subject framing. The other two (Unetixs Vascular and ExThera Medical) are framed against PMA and IDE pathways, not the QMS itself.
This is what enforcement lag looks like. Warning letters trail inspections by six to eighteen months. The inspections behind those three letters happened before February 2, which is why the citation language reads against a regulation that no longer exists in its old form. The 483 cohort above is 90.6% ISO 13485 framed. The published WLs from the same agency are not. They will be, in about two cycles.
For quality leaders: stop using published WL language as your QMSR readiness benchmark. The substance underneath the QSR framing is the same supplier-controls, complaint-handling, and design-planning failures that ISO §7.4.1, §8.2.2, and §7.1 now name. Translate it yourself, before the inspector arrives.
If your QMS still references 21 CFR 820 without the ISO mapping alongside, you are reading one lexicon behind the one FDA is already writing in.
Source: FDA CDRH Warning Letter Solr Index, primary-source pull through 2026-05-05.